$699.00
In Stock
Teysuno is an antitumor agent — an antimetabolite.
Teysuno is a combined oral fluoropyrimidine antitumor drug that includes a fixed combination of 3 active ingredients – tegafur, gimeracil and oteracil.
After absorption in the gastrointestinal tract, tegafur is transformed into the active form fluorouracil (FU), which has pronounced antitumor activity, without increasing the toxic effect of FU.
Gimeracil is a competitive inhibitor of dihydropyrimidine dehydrogenase (DPD), its action is to inhibit the destruction of FU in the human body.
Oteracil is an inhibitor of orotate phosphoribosyltransferase (OPRT), reduces the severity of the local irritant effect of FU on the unchanged mucous membrane of the gastrointestinal tract and the severity of inflammatory reactions caused by FU.
The combination drug Teysuno, containing a fixed combination of tegafur, gimeracil and oteracil potassium in a molar ratio of 1:0.4:1, while maintaining the antitumor activity of FU, has a less pronounced toxic effect compared to FU monotherapy.
It is used to treat advanced gastric cancer in adults in combination with cisplatin.
Active ingredient: tegafur, oteracil, gimeracil
Prescription medicine
The drug is delivered from Germany
